AP1893A - Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof - Google Patents
Compounds specific to adenosine A1, A2A and A3 receptor and uses thereofInfo
- Publication number
- AP1893A AP1893A APAP/P/2003/002807A AP2003002807A AP1893A AP 1893 A AP1893 A AP 1893A AP 2003002807 A AP2003002807 A AP 2003002807A AP 1893 A AP1893 A AP 1893A
- Authority
- AP
- ARIPO
- Prior art keywords
- adenosine
- receptor
- compounds
- compounds specific
- receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/728,607 US6664252B2 (en) | 1999-12-02 | 2000-12-01 | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
US09/728,616 US7160890B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A3 receptor and uses thereof |
US09/728,316 US6680322B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A1 receptors and uses thereof |
PCT/US2001/045280 WO2002057267A1 (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2003002807A0 AP2003002807A0 (en) | 2003-06-30 |
AP1893A true AP1893A (en) | 2008-09-23 |
Family
ID=27419112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/2003/002807A AP1893A (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1347980A4 (xx) |
JP (1) | JP4579497B2 (xx) |
CN (1) | CN1263757C (xx) |
AP (1) | AP1893A (xx) |
AU (1) | AU2002248151B2 (xx) |
BR (1) | BR0115847A (xx) |
CA (1) | CA2430577A1 (xx) |
CZ (1) | CZ20031831A3 (xx) |
EA (1) | EA007254B1 (xx) |
HU (1) | HUP0400692A3 (xx) |
IL (1) | IL155962A0 (xx) |
ME (1) | MEP35308A (xx) |
MX (1) | MXPA03004717A (xx) |
NO (1) | NO327207B1 (xx) |
NZ (1) | NZ525885A (xx) |
OA (1) | OA13295A (xx) |
PL (1) | PL363245A1 (xx) |
WO (1) | WO2002057267A1 (xx) |
YU (1) | YU42703A (xx) |
ZA (1) | ZA200303729B (xx) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5090531A (en) * | 1990-01-10 | 1992-02-25 | Lord Corporation | Electrophoretic fluid differential |
OA12147A (en) | 1998-06-02 | 2006-05-05 | Osi Pharm Inc | PyrroloÄ2,3dÜpyrimidine compositions and their use. |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
DE10148883A1 (de) * | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | Pyrimidinderivate |
EP1450811B1 (en) * | 2001-11-30 | 2009-10-21 | OSI Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
CA2469316A1 (en) * | 2001-12-07 | 2003-06-19 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as gsk-3 inhibitors |
EA007468B1 (ru) | 2001-12-20 | 2006-10-27 | Оси Фармасьютикалз, Инк. | Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение |
CN101973998A (zh) | 2001-12-20 | 2011-02-16 | Osi药物公司 | 吡咯并嘧啶A2b选择性拮抗剂化合物 |
AU2003270701B2 (en) * | 2002-10-31 | 2009-11-12 | Amgen Inc. | Antiinflammation agents |
HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
US8796293B2 (en) | 2006-04-25 | 2014-08-05 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
TW200808819A (en) * | 2006-06-19 | 2008-02-16 | Solvay Pharm Gmbh | Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty |
WO2009047563A1 (en) | 2007-10-11 | 2009-04-16 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
NZ586642A (en) | 2008-01-11 | 2012-04-27 | Natco Pharma Ltd | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
PL2694056T3 (pl) | 2011-04-01 | 2020-03-31 | Astrazeneca Ab | Leczenie terapeutyczne |
MY175800A (en) | 2011-11-30 | 2020-07-09 | Astrazeneca Ab | Combination treatment of cancer |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
WO2013182580A1 (en) * | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
CA3190653A1 (en) | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Ltd. | Bicyclic bromodomain inhibitors |
EP3010918B1 (en) | 2013-06-21 | 2018-08-15 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
KR20160038008A (ko) | 2013-07-31 | 2016-04-06 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 억제제로서 신규 퀴나졸리논 |
US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
JP2017537946A (ja) | 2014-12-11 | 2017-12-21 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | ブロモドメイン阻害剤としての置換複素環 |
WO2016097863A1 (en) | 2014-12-17 | 2016-06-23 | Zenith Epigenetics Corp. | Inhibitors of bromodomains |
CN108349977B (zh) * | 2015-01-20 | 2021-05-25 | 无锡福祈制药有限公司 | Jak抑制剂 |
PT3290418T (pt) | 2015-04-29 | 2019-07-16 | Wuxi Fortune Pharmaceutical Co Ltd | Inibidores de janus quinase (jak) |
PT3305788T (pt) | 2015-05-29 | 2020-09-25 | Wuxi Fortune Pharmaceutical Co Ltd | Inibidor da janus cinase |
CN105771672B (zh) * | 2016-04-18 | 2018-03-02 | 天津工业大学 | 一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法 |
US11066413B2 (en) * | 2017-03-07 | 2021-07-20 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof |
CN108017584B (zh) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3腺苷受体的小分子拮抗剂 |
KR20210033444A (ko) * | 2018-06-04 | 2021-03-26 | 엑스사이언티아 엘티디 | 아데노신 수용체 길항제로서 피라졸로피리미딘 화합물 |
CN110128316B (zh) * | 2019-05-22 | 2021-08-31 | 北京大学深圳研究生院 | 5位取代的β-脯氨酸及其衍生物的制备方法 |
CN110272373B (zh) * | 2019-07-02 | 2022-07-29 | 天津国际生物医药联合研究院 | 一种具有选择性的腺苷a1受体拮抗剂及其应用 |
CN114085178A (zh) * | 2021-12-29 | 2022-02-25 | 苏州楚凯药业有限公司 | 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062518A1 (en) * | 1998-06-02 | 1999-12-09 | Osi Pharmaceuticals, Inc. | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
WO2001039777A1 (en) * | 1999-12-02 | 2001-06-07 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
WO2003048120A2 (en) * | 2001-11-30 | 2003-06-12 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0173172B1 (ko) * | 1992-12-17 | 1999-02-01 | 알렌 제이. 스피겔 | Crf 길항제로서의 피롤로피리미딘 |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
-
2001
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/xx unknown
- 2001-11-30 IL IL15596201A patent/IL155962A0/xx unknown
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 YU YU42703A patent/YU42703A/sh unknown
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/pt not_active Application Discontinuation
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/ja not_active Expired - Fee Related
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en active IP Right Grant
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/cs unknown
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/es active IP Right Grant
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/hu unknown
- 2001-11-30 CN CNB018224601A patent/CN1263757C/zh not_active Expired - Fee Related
- 2001-11-30 EA EA200300628A patent/EA007254B1/ru not_active IP Right Cessation
- 2001-11-30 PL PL01363245A patent/PL363245A1/xx not_active Application Discontinuation
-
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/no not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062518A1 (en) * | 1998-06-02 | 1999-12-09 | Osi Pharmaceuticals, Inc. | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
WO2001039777A1 (en) * | 1999-12-02 | 2001-06-07 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
WO2003048120A2 (en) * | 2001-11-30 | 2003-06-12 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
Also Published As
Publication number | Publication date |
---|---|
EP1347980A1 (en) | 2003-10-01 |
NO327207B1 (no) | 2009-05-11 |
MEP35308A (en) | 2011-02-10 |
OA13295A (en) | 2007-04-13 |
BR0115847A (pt) | 2004-02-25 |
CN1489590A (zh) | 2004-04-14 |
IL155962A0 (en) | 2003-12-23 |
AP2003002807A0 (en) | 2003-06-30 |
CZ20031831A3 (cs) | 2004-05-12 |
MXPA03004717A (es) | 2004-06-30 |
EP1347980A4 (en) | 2005-02-09 |
EA200300628A1 (ru) | 2003-12-25 |
AU2002248151B2 (en) | 2008-02-21 |
YU42703A (sh) | 2006-03-03 |
NO20032482L (no) | 2003-07-28 |
CN1263757C (zh) | 2006-07-12 |
PL363245A1 (en) | 2004-11-15 |
HUP0400692A3 (en) | 2007-09-28 |
NO20032482D0 (no) | 2003-06-02 |
WO2002057267A1 (en) | 2002-07-25 |
HUP0400692A2 (hu) | 2004-07-28 |
ZA200303729B (en) | 2004-05-14 |
EA007254B1 (ru) | 2006-08-25 |
JP4579497B2 (ja) | 2010-11-10 |
NZ525885A (en) | 2005-01-28 |
JP2004517896A (ja) | 2004-06-17 |
CA2430577A1 (en) | 2002-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP1893A (en) | Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof | |
WO2001039777A8 (en) | Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof | |
WO2003048120A3 (en) | 2-aryl pyrrologpyrimidines for a1 and a3 receptors | |
NZ522326A (en) | Adenosine A2A receptor antagonists | |
AP2003002911A0 (en) | An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases. | |
WO2002043652A3 (en) | Anti-proliferative drugs | |
PT1194049E (pt) | Peca de vestuario com capacidade respiratoria, para ser vestida com o intuito de melhorar o conforto do corpo humana | |
BR0115067A (pt) | Análogos de gnrh para tratamento de incontinência urinária | |
MXPA03009185A (es) | Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson. | |
EE200000253A (et) | Seentevastase toimeaine kasutamine ravimite valmistamiseks, mis on ette nähtud mitteinvasiivsetest seenorganismidest tingitud haiguste raviks või vältimiseks | |
MXPA02010801A (es) | Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados. | |
WO2005097140A3 (en) | Selective antagonists of a2a adenosine receptors | |
BR0009480A (pt) | Soluções de poliuretano com unidades de estrutura de alcoxissilano | |
AR023966A1 (es) | Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion | |
BRPI0409359A (pt) | análogos quiméricos de somatostatina-dopamina | |
NO996583D0 (no) | Absorberende gjenstander til engangsbruk, med forbedret tilpasning til kroppsanatomien | |
EE200100689A (et) | IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon | |
IL156069A0 (en) | Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma | |
MXPA03003032A (es) | Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos. | |
TWI256388B (en) | Pharmaceutical combination | |
MY142646A (en) | Chemokine receptor antagonists and methods of use therefor | |
BR0115413A (pt) | Tratamento de ejaculação precoce | |
WO1999038500A3 (en) | The human calcium-sensing receptor in the detection and treatment of cancer | |
GB9930085D0 (en) | Medicaments | |
AU2003264195A8 (en) | Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system |